Análisis de 1.000 casos de estudios metabólicos en Chile con PET 18Flúor-deoxiglucosa (FDG)
-
Teresa Massardo [1] ; M. Josefina Jofré [2] ; Paulina Sierralta [2] ; José Canessa [2] ; Patricio González [1] ; Pamela Humeres [2] ; Robert Valdebenito [2]
-
[1] Universidad de Chile
Universidad de Chile
Santiago, Chile
-
[2] Hospital Militar de Santiago
Hospital Militar de Santiago
Santiago, Chile
-
- Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 135, Nº. 3, 2007, págs. 375-383
- Idioma: español
- Títulos paralelos:
- Chilean experience with the use of 18F-deoxyglucose positron emission tomography
- Enlaces
-
Resumen
Background: Clinical oncology is the main application of 18F-deoxyglucose (FDG) positron emission tomography (PET). Aim: To evaluate the first 1,000 patients studied with FDG PET in Chile. Material and methods: Retrospective analysis of 1,000 patients (aged between 1 and 94 years, 550 females) studied with FDG PET, since 2003. All studies were performed in a high resolution Siemens Ecat-Exact HR (+). All reports were based on the visual analysis of three plane and three-dimensional images. Results: Ninety seven percent of exams were done for oncological indications, mainly lung lesions, lymphoma, colorectal and gastroesophageal, cancer and breast tumors. Only 1% of patients had brain tumors. Non tumor neurological indications corresponded to 1.7%. Cardiac studies were only 0.3% and inflammatory process corresponded to 1%. The 5.6% corresponded to pediatric population. Six percent of patients were aged less than 18 years and in 50% of them, the indication was oncological, mainly lymphomas, brain tumors, endocrine cancers and sarcomas. The remaining 50% had a neurological indications, mainly for refractory epilepsy. Conclusions: PET FDG imaging was effective in the management of diverse diseases of children and adults
